Signal active
Investment Firm
Overview
Perceptive Advisors is a privately owned hedge fund sponsor. The firm invests in the public equity markets across the globe. It employs a long/short equity strategy as a hedging technique while investing. The firm typically invests in the biotechnology and life sciences sectors to make its investments. Perceptive Advisors is based in New York, New York.
Highlights
1999
Financial Services
11-50
279
95
144
Early Stage Venture, Late Stage Venture, Private Equity, Seed
Hedge Fund
Location
New York, New York, United States, North America
Contact Information
Social
Profile Resume
Perceptive Advisors, established in 1999 and headquartered in New York, New York, United States, North America., specializes in Early Stage Venture, Late Stage Venture, Private Equity, Seed investments across Biotechnology, Health Care, Pharmaceutical, Medical, Oncology, Financial Services, Venture Capital, Finance, Biopharma, Therapeutics. The organization boasts a portfolio of 277 investments, with an average round size of $109.7M and 144 successful exits. Their recent investments include EUSA Pharma, Iroquois Capital, Highbridge Capital Management, Sevion Therapeutics, Alpha Capital. The highest investment round they participated in was $3108.3B. Among their most notable exits are EUSA Pharma and Iroquois Capital. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.
Investment portfolio
279
76
95
144
Investments
279
Annouced Date | Organization Name | Industry | Money Raised |
---|---|---|---|
Jun 18, 2024 | - | - | 190.0M |
Jun 18, 2024 | InSightec | Biotechnology | 150.0M |
Jul 26, 2024 | Confo Therapeutics | Biotechnology | 65.1M |
Aug 12, 2024 | scPharmaceuticals | Biotechnology | 125.0M |
Exits
144
Funding Timeline
279
0
4
Funding Rounds
279
Perceptive Advisors has raised 279 rounds. Their latest funding was raised on Aug 12, 2024 from a Post-IPO Debt - scPharmaceuticals round.
Annouced Date | Transaction Name | Number of Investors | Money Raised | Lead Investor |
---|---|---|---|---|
Jun 18, 2024 | Series B - Marea Therapeutics | - | 190.0M | - |
Jun 18, 2024 | Private Equity Round - InSightec | - | 150.0M | - |
Jul 26, 2024 | Series B - Confo Therapeutics | - | 65.1M | - |
Aug 12, 2024 | Post-IPO Debt - scPharmaceuticals | - | 125.0M | - |
Investors
0
There is no funding round available on this profile
Fund raised
2
Susa Ventures has raised a total of $590M across 6 funds, their latest being Susa Ventures Opportunities II. This fund was announced on Aug 30, 2021 and raised a total of $250M.
Annouced Date | Fund Name | Money Raised |
---|---|---|
May 10, 2013 | OTPPLESS | 1.0M |
May 11, 2013 | OTPPLESS | 1.0M |
Invest in industries
Recent Activity
There is no recent news or activity for this profile.